Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference - Presentations include new data and analyses from Phase III trials across the respiratory portfolio, including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF)- Key data and analyses from Phase III trials of investigational tiotropium/olodaterol Respimat® for COPD and investigational tiotropium Respimat® for asthma will be presented- New data and analyses for OFEV® (nintedanib) capsules for the treatment of IPF will be presented

RIDGEFIELD, Conn., May 5, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that 29 abstracts from the company's respiratory portfolio will be presented at the 2015 American Thoracic Society (ATS) International Conference taking place May 15-20 in Denver, including data on investigational therapies for chronic obstructive pulmonary disease (COPD) and asthma, and on approved products for idiopathic pulmonary fibrosis (IPF) and COPD. Of the 29 accepted abstracts, 19 are on COPD, including key data from the Phase III TONADO™ trials of late-stage, investigational tiotropium/olodaterol Respimat®.   "We are proud of our long-standing commitment to...